Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoCyclo
- Development stage
- Preclinical
- Lead developer
- Immune Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
NanoCyclo is a nano-encapsulated formulation of cyclosporin developed for topical administration. It is designed to enhance the delivery and efficacy of cyclosporin, an immunosuppressant drug, in the treatment of inflammatory skin diseases such as atopic dermatitis and psoriasis. The nano-encapsulation aims to improve skin penetration, reduce systemic exposure, and potentially minimize side effects compared to conventional formulations. The drug was developed by Immune Pharmaceuticals in collaboration with BioNanoSim and has been in late-stage preclinical development with plans for clinical trials targeting dermatological indications[5][7].
- Brand names
- NanoCyclo
- Other names
- NanoCyclo
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on NanoCyclo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoCyclo.